Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has signed a deal with Tibotec Pharmaceuticals to develop and commercialize a new combination antiretroviral drug that contains investigational pharmacoenhancing cobicistat and protease inhibitor Prezista (darunavir).
Subscribe to our email newsletter
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide.
Gilead is responsible to develop, manufacture and commercialize cobicistat as a stand-alone product and for use in combination with other agents.
Additionally, both the parties are also in negotiations to develop and commercialize another combined drug combining Prezista, Emtriva, GS 7340 and cobicistat.
The agreement is subject to regulatory approval.